Ritedose to Manufacture Verona Pharma’s Novel COPD Drug Ohtuvayre

• The Ritedose Corporation has partnered with Verona Pharma plc to develop and manufacture Ohtuvayre, a novel COPD treatment.

• Ohtuvayre has been approved by the FDA and is the first new inhaled product for COPD in over 20 years.

The Ritedose Corporation has entered into a partnership with Verona Pharma plc to serve as the development and manufacturing partner for Ohtuvayre, a novel therapy for Chronic Obstructive Pulmonary Disease (COPD). This collaboration marks a significant advancement in COPD treatment, with Ohtuvayre being the first new inhaled product approved for maintenance therapy in over two decades.

Ohtuvayre received approval from the U.S. Food and Drug Administration (FDA) on June 26. The drug features a novel mechanism of action, specifically as a PDE3 and PDE4 inhibitor, and is administered via a standard jet nebulizer. It aims to address daily symptoms such as breathlessness and persistent coughing that are common in COPD patients despite existing therapies.

Jody Chastain, President and CEO of The Ritedose Corporation, stated, “We are proud to partner with Verona Pharma for the development and manufacturing of Ohtuvayre. We have the resources to deliver significant doses of Ohtuvayre on time, every time.”

David Zaccardelli, Pharm. D., President and CEO of Verona Pharma, emphasised the importance of the collaboration: “Ohtuvayre’s novel profile can change the treatment paradigm for COPD, and we wanted to partner with Ritedose to ensure the highest manufacturing quality.”